- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 239/72 - QuinazolinesHydrogenated quinazolines
Patent holdings for IPC class C07D 239/72
Total number of patents in this class: 256
10-year publication summary
8
|
17
|
7
|
9
|
10
|
12
|
14
|
14
|
12
|
5
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Boehringer Ingelheim International GmbH | 4650 |
9 |
Merck Patent GmbH | 5831 |
8 |
Janssen Pharmaceutica N.V. | 3392 |
6 |
Gilead Sciences, Inc. | 2036 |
6 |
Bristol-myers Squibb Company | 4898 |
5 |
Merck Sharp & Dohme LLC | 3748 |
5 |
Merck Sharp & Dohme Corp. | 2194 |
4 |
Nerviano Medical Sciences S.r.l. | 256 |
4 |
University of Pittsburgh - Of the Commonwealth System of Higher Education | 3151 |
4 |
Emory University | 1626 |
3 |
Exelixis, Inc. | 399 |
3 |
Hutchison MediPharma Enterprises Limited | 13 |
3 |
Myriad Pharmaceuticals, Inc. | 10 |
3 |
Reata Pharmaceuticals, Inc. | 123 |
3 |
Sichuan Huiyu Pharmaceutical Co., Ltd. | 29 |
3 |
Wuhan LL Science and Technology Development Co., Ltd | 72 |
3 |
Hutchmed Limited | 26 |
3 |
Sichuan Huiyu Seacross Pharmaceutical Technology Co., Ltd. | 21 |
3 |
Genentech, Inc. | 3976 |
2 |
President and Fellows of Harvard College | 5976 |
2 |
Other owners | 174 |